Clinical and Translational Oncology

, Volume 10, Issue 11, pp 688–696

Langerhans cell histiocytosis

  • Joan Manel Gasent Blesa
  • Vicente Alberola Candel
  • Carlos Solano Vercet
  • Juan Laforga Canales
  • Christof Semler
  • M. Rosa Pérez Antolí
  • Carlos Rodríguez-Galindo
Educational Series

DOI: 10.1007/s12094-008-0275-9

Cite this article as:
Gasent Blesa, J.M., Alberola Candel, V., Vercet, C.S. et al. Clin Transl Oncol (2008) 10: 688. doi:10.1007/s12094-008-0275-9

Abstract

Langerhans cell histiocytosis (LCH) is a poorly understood proliferative disease, with different patterns of clinical presentation. Currently it is classified according to the number and type of system involved and the degree of organ dysfunction. The aetiology of the disease remains uncertain, and in some cases the disease is polyclonal, suggesting a reactive condition. Many cytokines have been implicated in the pathogenesis of LCH. Different therapeutic approaches can be considered depending on the affected organ, including surgery, radiotherapy and chemotherapy. Long-term organ dysfunction may remain, despite disease control and/or eradication, making indefinite supportive treatment mandatory. Here we present a literature review on all of the aspects of the disease, treatment approaches and existing protocols, and finally an adult clinical case.

Keywords

Langerhans’s cell histiocytosisAdultReview

Copyright information

© Feseo 2008

Authors and Affiliations

  • Joan Manel Gasent Blesa
    • 1
  • Vicente Alberola Candel
    • 2
  • Carlos Solano Vercet
    • 3
  • Juan Laforga Canales
    • 1
  • Christof Semler
    • 4
  • M. Rosa Pérez Antolí
    • 4
  • Carlos Rodríguez-Galindo
    • 5
  1. 1.Hospital General Universitari Marina AltaDènia, AlacantSpain
  2. 2.Hospital Universitari Arnau de VilanovaValènciaSpain
  3. 3.Hospital Clinic UniversitariValènciaSpain
  4. 4.Centro Clínico Euroclínica JàveaJàveaSpain
  5. 5.Department of OncologySt Jude Children’s Research HospitalMemphisUSA